Home › Head and Neck Cancer › NCT06108089

Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Newly diagnosed HNSCC (head and neck squamous cell carcinoma) by biopsy or fine needle aspiration originating from the oral cavity, larynx, hypopharynx, nasopharynx, and oropharynx
* Patients are scheduled to undergo chemoradiotherapy or surgery
* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

* Pregnant patients
* Patients with claustrophobia
* Patients with pacemaker, spinal stimulator, or cochlear implant that are not MR compatible or any other metallic objects in the body
* Patients who had been treated for HNC, either surgery, radiation therapy, or chemotherapy
* Patients with thyroid, skin, sinonasal, and salivary gland cancer.
* Abnormal kidney function defined as estimated glomerular filtration rate (eGRF) \< 30 mL/min/1.73 m2
* Patients with uncontrolled diabetes
* Patients who obtained outside FDG-PET/CT prior to initial treatment

About the study

Tumor hypoxia is one of the physiological factors for treatment resistance and likely contributes to poor overall survival among patients with head and neck cancer (HNC). Identifying hypoxic features of HNC may allow the personalizing treatment plan. The investigators propose multiparametric Hypoxia MR (HMR) imaging using diffusion, perfusion, and oxygenation as non-invasive, in-vivo imaging components of a hypoxia phenotype. Assessing the hypoxia phenotypes' expression will be critically important for characterizing and predicting CRT response among patients with advanced HNC.

A prospective cohort study will be conducted used multiparametric MR (MPMR) imaging correlated with treatment response assessed by 3 months fluorodeoxyglucose-positron emission tomography (FDG-PET). The image analysis approach will be developed to incorporate FDG-PET and quantitative MRI characteristics of tumor (ADC, oxygen-enhanced T1 and T2\* maps, and volume transfer constant (Ktrans) to facilitate 3D visualization of multiparametric information. This proposed study's overarching goal is to develop and validate multiparametric HMR imaging using 18F - (fluoromisonidazole) FMISO-PET and immunohistochemistry (IHC) as the standard of references.

What is being tested

• [18F]MISO-PET/CT (diagnostic test)

Sponsor: University of Utah · Participants: 20 · Started: Jun 28, 2024

Contact the study team

• Olivia Pratt · Phone: (801)585-6142
• Nousheen Alasti · Phone: (801)585-6142

Official record on ClinicalTrials.gov — NCT06108089

Locations in the U.S.

Conditions

• Head and Neck Cancer

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.